SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Crawford Raphael Goszcz

(Last) (First) (Middle)
ALBEMARLE CORPORATION,
4250 CONGRESS STREET, SUITE 900

(Street)
CHARLOTTE NC 28209

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2019
3. Issuer Name and Ticker or Trading Symbol
ALBEMARLE CORP [ ALB ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, Catalysts
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (1) (1) Common Stock 3,090 65 D
Stock Option (2) (2) Common Stock 3,069 63.84 D
Stock Option (3) (3) Common Stock 3,720 56.08 D
Stock Option (4) (4) Common Stock 7,784 56.56 D
Stock Option (5) (5) Common Stock 6,255 92.93 D
Stock Option (6) (6) Common Stock 5,021 118.75 D
Stock Option (7) (7) Common Stock 7,218 91 D
Restricted Stock Units (8) (9) Common Stock 2,212 (10) D
Restricted Stock Units (11) (9) Common Stock 1,884 (10) D
Restricted Stock Units (12) (9) Common Stock 1,580 (10) D
Restricted Stock Units (13) (9) Common Stock 2,198 (10) D
Explanation of Responses:
1. On February 22, 2013, the reporting person was granted a 10-year option exercisable for 3,090 shares of Common Stock. The option fully vested on 2/22/2018.
2. On February 24, 2014, the reporting person was granted a 10-year option exercisable for 3,069 shares of Common Stock. The option fully vested on 2/24/2019.
3. On February 24, 2015, the reporting person was granted a 10-year option exercisable for 3,720 shares of Common Stock. 2/3 of the Option vested on 2/24/2018 and 2/24/2019. The remaining 1/3 of the option will vest on 2/24/2020.
4. On February 24, 2016, the reporting person was granted a 10-year option exercisable for 7,784 shares of Common Stock. The option cliff-vested on 2/26/2019.
5. On February 24, 2017, the reporting person was granted a 10-year option exercisable for 6,255 shares of Common Stock. The option cliff-vests on 2/24/2020.
6. On February 23, 2018, the reporting person was granted a 10-year option exercisable for 5,021 shares of Common Stock. The option cliff-vests on 2/23/2021.
7. On February 26, 2019, the reporting person was granted a 10-year option exercisable for 7,218 shares of Common Stock. The option cliff-vests on 2/26/2022.
8. Restricted Stock Units granted on 2/26/2016. First 50% vested on 2/26/2019 and second 50% vests on 2/26/2020.
9. No expiration date.
10. Each Restricted Stock Unit converts to 1 share of Common Stock.
11. Restricted Stock Units granted on 2/24/2017. First 50% vests on 2/24/2020 and second 50% vests on 2/24/2021.
12. Restricted Stock Units granted on 2/23/2018. First 50% vests on 2/23/2021 and second 50% vests on 2/23/2022.
13. Restricted Stock Units granted on 2/26/2019. First 50% vests on 2/26/2022 and second 50% vests on 2/26/2023.
Remarks:
Exhibit List Exhibit 24 - Power of Attorney
/s/ Ander Krupa, attorney-in-fact 05/17/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                               POWER OF ATTORNEY

     Know all by these presents, that the undersigned hereby constitutes and
appoints each of Karen G. Narwold, Ander Krupa, Sarah E. Marshik and Brenda J.
Mareski, or either of them acting singly and with full power of substitution,
the undersigned's true and lawful attorney-in-fact to:


     (1)    execute for and on behalf of the undersigned, in the undersigned's
            capacity as an officer and/or director of Albemarle Corporation
            (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a)
            of the Securities Exchange Act of 1934 and the rules thereunder;
     (2)    do and perform any and all acts for and on behalf of the undersigned
            that may be necessary or desirable to complete and execute any such
            Form 3, 4 or 5, complete and execute any amendment or amendments
            thereto, and timely file such form with the United States Securities
            and Exchange Commission and any stock exchange or similar authority;
            and
     (3)    take any other action of any type whatsoever in connection with the
            foregoing that, in the opinion of such attorney-in-fact, may be of
            benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by such
            attorney-in-fact on behalf of the undersigned pursuant to this
 Power
            of Attorney shall be in such form and shall contain such terms and
            conditions as such attorney-in-fact may approve in such attorney-in-
            fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
 executed as of this 9th day of May, 2019.




                                                    /s/ Raphael G. Crawford
                                                    Raphael G. Crawford